This systematic review and meta-analysis of the literature for the use of stereotactic ablative radiotherapy (SABR) for renal cell carcinoma (RCC), looks at data from 372 patients (383 tumours), most of whom were inoperable.

The study concluded that renal SABR is effective locally and is well tolerated for primary RCC, despite treatment of larger tumours in older, mostly inoperable patients. SABR is a high-precision, non-invasive radiation treatment requiring few outpatient visits, and is a safe and effective option for primary RCC.

Read more in UroToday here